ArticleAntibiotics (Basel, Switzerland)2020
Multiple Drug Resistance Patterns in Various Phylogenetic Groups of Hospital-Acquired Uropathogenic
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Burden of extended-spectrum beta-lactamase-producing Enterobacteriaceae among cancer patients in Africa: a systematic review and meta-analysis.Access microbiology · 2026Article
- Prevalence of pathogens associated with neonatal gastrointestinal infections: a systematic review and meta-analysis.Gut pathogens · 2025Review
- Antibiotic Resistance Profile of EnterovirulentInternational journal of microbiology · 2025Article
- Avian pathogenicVeterinary world · 2024Review
- Repurposing carvacrol, cinnamaldehyde, and eugenol as potential anti-quorum sensing agents against uropathogenic Escherichia coli isolates in Alexandria, Egypt.BMC microbiology · 2023Article
- The Triple Crown: NO, CO, and HPharmacology & therapeutics · 2023Review
- Phenotyping and Genotyping Evaluation ofArchives of Razi Institute · 2023Article
- Uropathogenic Escherichia coli endeavors: an insight into the characteristic features, resistance mechanism, and treatment choice.Archives of microbiology · 2023Review
- Antibacterial effect of vitamin C against uropathogenic E. coli in vitro and in vivo.BMC microbiology · 2023Article
- Development of sensitizer peptide-fused endolysin Lys1S-L9P acting against multidrug-resistant gram-negative bacteria.Frontiers in microbiology · 2023Article
- Studies on Virulence and Extended-SpectrumBioMed research international · 2022Article
- Bacterial Profile and Antibiotic Resistance among Cancer Patients with Urinary Tract Infection in a National Tertiary Cancer Hospital of Nepal.Tropical medicine and infectious disease · 2021Article
- Genomic Insights into a Colistin-Resistant UropathogenicMicroorganisms · 2021Article
- Comparative Evaluation ofAntibiotics (Basel, Switzerland) · 2020Article
- Stewardship of Antibiotics for Multidrug-Resistant Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer patients are more susceptible to several bacterial infections, particularly urinary tract infections caused by uropathogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.